Cargando…

Potential mechanisms of resistance to venetoclax and strategies to circumvent it

BACKGROUND: Venetoclax (ABT-199), a first-in-class orally bioavailable BCL-2-selective inhibitor, was recently approved by the FDA for use in patients with 17p-deleted chronic lymphocytic leukemia who have received prior therapy. It is also being evaluated in numerous clinical trials for treating pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tahir, Stephen K., Smith, Morey L., Hessler, Paul, Rapp, Lisa Roberts, Idler, Kenneth B., Park, Chang H., Leverson, Joel D., Lam, Lloyd T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457565/ https://www.ncbi.nlm.nih.gov/pubmed/28578655 http://dx.doi.org/10.1186/s12885-017-3383-5

Ejemplares similares

Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax
por: Ackler, Scott, et al.
Publicado: (2015)

Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?
por: Leverson, Joel D., et al.
Publicado: (2018)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2015)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2016)

The Strategies of Pathogen-Oriented Therapy on Circumventing Antimicrobial Resistance
por: Shang, Zifang, et al.
Publicado: (2020)

Mechanisms of venetoclax resistance and solutions
por: Liu, Jiachen, et al.
Publicado: (2022)

P409: BCL-2/BCL-XL INHIBITION INDUCES APOPTOSIS AND CIRCUMVENTS VENETOCLAX RESISTANCE IN TP53-MUTATED ACUTE MYELOID LEUKEMIA
por: Vänttinen, Ida, et al.
Publicado: (2023)

Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer
por: Zhang, Haichao, et al.
Publicado: (2015)

Venetoclax resistance: mechanistic insights and future strategies
por: Ong, Faustine, et al.
Publicado: (2022)

Strategies to circumvent the CFTR defect in cystic fibrosis
por: Becq, Frédéric, et al.
Publicado: (2013)

Exploring Nanotechnology as a Strategy to Circumvent Antimicrobial Resistance in Bone and Joint Infections
por: Skosana, Phumzile P., et al.
Publicado: (2023)

Circumventing the Greatwall
por: Short, Ben
Publicado: (2014)

Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia
por: Chyla, Brenda, et al.
Publicado: (2018)

Drug Repurposing to Circumvent Immune Checkpoint Inhibitor Resistance in Cancer Immunotherapy
por: To, Kenneth K. W., et al.
Publicado: (2023)

CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma
por: Thieme, Elana, et al.
Publicado: (2023)

Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells
por: Ludwig, Lindsey M., et al.
Publicado: (2021)

Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy
por: Shin, Dong Ho, et al.
Publicado: (2021)

Fecal microbiota transplantation: can it circumvent resistance to PD-1 blockade in melanoma?
por: Derosa, Lisa, et al.
Publicado: (2021)

Prospects for circumventing aminoglycoside kinase mediated antibiotic resistance
por: Shi, Kun, et al.
Publicado: (2013)

Marine Natural Products as Models to Circumvent Multidrug Resistance
por: Long, Solida, et al.
Publicado: (2016)

Bordetella parapertussis Circumvents Neutrophil Extracellular Bactericidal Mechanisms
por: Gorgojo, Juan, et al.
Publicado: (2017)

A Chemical-Intervention Strategy To Circumvent Peptide Hydrolysis by d-Stereoselective Peptidases
por: Bann, Samantha J., et al.
Publicado: (2019)

Bispecific prodrug nanoparticles circumventing multiple immune resistance mechanisms for promoting cancer immunotherapy
por: Ye, Jiayi, et al.
Publicado: (2022)

Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia
por: Kater, Arnon P., et al.
Publicado: (2021)

Strategies to Circumvent Host Innate Immune Response by Hepatitis C Virus
por: Patra, Tapas, et al.
Publicado: (2019)

mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3- and Blimp-1-mediated BCL-2 upregulation
por: Osada, Naoki, et al.
Publicado: (2021)

Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice.
por: Chauffert, B., et al.
Publicado: (1990)

Cephem‐Pyrazinoic Acid Conjugates: Circumventing Resistance in Mycobacterium tuberculosis
por: Cole, Malcolm S., et al.
Publicado: (2022)

A platinum-based hybrid drug design approach to circumvent acquired resistance to molecular targeted tyrosine kinase inhibitors
por: Wei, Yuming, et al.
Publicado: (2016)

Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
por: Yue, XiaoYan, et al.
Publicado: (2020)

Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC
por: MacDonagh, Lauren, et al.
Publicado: (2017)

DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition
por: Kerkhofs, Martijn, et al.
Publicado: (2020)

Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer
por: Tiwary, Richa, et al.
Publicado: (2011)

Multidrug Resistance in Cancer Circumvented Using a Cytosolic Drug Reservoir
por: Fan, Li, et al.
Publicado: (2017)

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2019)

Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance
por: Pedraza-Sánchez, Sigifredo, et al.
Publicado: (2023)

MicroRNA: a prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy
por: To, Kenneth KW
Publicado: (2013)

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia
por: Tahir, Stephen K., et al.
Publicado: (2023)

Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy
por: Popovic, Relja, et al.
Publicado: (2021)

Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells
por: Bodo, Juraj, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dc95t6qg1gf5eiapsm8tri8eae